A Phase 1, Open-Label Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of RG-012 for Injection in Subjects With Alport Syndrome

Trial Profile

A Phase 1, Open-Label Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of RG-012 for Injection in Subjects With Alport Syndrome

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Jul 2018

At a glance

  • Drugs RG 012 (Primary)
  • Indications Hereditary nephritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Regulus Therapeutics
  • Most Recent Events

    • 06 Jul 2018 Status changed from recruiting to active, no longer recruiting.
    • 10 May 2018 According to a Regulus Therapeutics media release, data from this trial are expected by year-end 2018.
    • 02 Apr 2018 Planned End Date changed from 1 Dec 2018 to 1 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top